Wharton’s Jelly Tissue Allograft for Connective Tissue Defects Surrounding Nerves in the Tarsal Tunnel: A Retrospective Case Series

• Published in: Reports (MDPI) Vol. 7; no. 1; p. 8
• Main Authors: Bruton, Ronald, Gilliland, Tracie L, Shou, John J, Woods, Crislyn G, Lambert, Naomi E, Barrett, Tyler C
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.01.2024
• Subjects: Antibodies; Care and treatment; Case studies; Connective tissue; Connective tissues; Cytomegalovirus; Datasets; Entrapment neuropathies; FDA approval; Feet; Health aspects; Hepatitis C; Homografts; Infectious diseases; Intervention; Laboratories; Medical research; Medicine, Experimental; Methods; nerve damage; neuropathy; Pain; Patients; Physiological aspects; Recovery (Medical); regenerative medicine; Surgery; Surgical outcomes; tarsal tunnel; Umbilical cord; West Nile virus; Wharton’s jelly; United States
• ISSN: 2571-841X; 2571-841X
• DOI: 10.3390/reports7010008

Caused by age or trauma, collapsed connective tissue can cause nerve entrapment and damage within the tarsal tunnel. Tarsal tunnel syndrome is relatively underdiagnosed. This study presents an intervention targeting damaged tissues surrounding the nerves and replacing the structural cushioning with a Wharton’s jelly tissue allograft. The eight patients in our study, selected from four clinical sites, had tarsal tunnel-related defects. Patient outcomes were tracked on a 90-day calendar utilizing the Numeric Pain Rating Scale (NPRS) and the Western Ontario and McMaster University Arthritis Index (WOMAC). All patients had failed standard care practices for at least six weeks. Each patient received a Wharton’s jelly tissue allograft to sites around the affected tarsal tunnel. No patients experienced adverse reactions. The percent change results calculated from the initial application to the 90-day follow-up showed an improvement of 59.43% in NPRS and a 37.58% improvement in WOMAC. This study provides evidence that WJ allograft applications are safe, minimally invasive, and efficacious for patients who have failed standard care treatments for tissue defects associated with tarsal tunnel syndrome. The limitations of this study include its small cohort size and nonblinded nature. The results of this study warrant further research to confirm the efficacy, optimal dose, protocol, and durability of Wharton’s jelly.